CEO Monthly Sept

18 CEO MONTHLY / AUGUST 2017 , TransMed7, LLC, amedical and technology based organization focused on the highly efficient development of innovative, minimally invasive medical devices aimed at providing new solutions for doctors and their patients, announces breast health chair appointment. New Leader in Breast Health for TransMed7 TransMed7, LLC, has announced the appointment of Richard E. Fine, MD, as Chair, Breast Health Team and Member, Executive Team of TransMed7’s Clinical and Scientific Advisory Board (CSAB). “We are honored to have Dr. Fine as Chair of the distinguished leaders in our Breast Health Team. He brings to our organization more than 20 years’ experience as a nationally recognized pioneer in breast care,” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO. “In his new role, he will be responsible for helping TransMed7 and particularly, our Breast Health Team, achieve their goal of developing critically needed, minimally-invasive medical technologies and getting them into the hands of clinicians for the benefit of their patients as rapidly as possible, with particular emphasis on launching Concorde™, our new platform technology for stereotactic and MRI based biopsy procedures, and Martinet™, our novel minimal access device for complete removal of target tissue.” Since 2012, Dr. Fine has been the Director of Education and Research at the Margaret West Comprehensive Breast Center. In addition, he is the Program Director, West Cancer Center Breast Surgical Oncology Fellowship and Associate Professor in the Department of Surgery, Division of Surgical Oncology at the University of Tennessee Health Science Center, College of Medicine. Dr. Fine holds or has held several positions of national prominence in breast care including Presidency of the American Society of Breast Surgeons from 2003-2004, Chairman of the Board of the American Society of Breast Surgeons, Chairman of the Board of the American Society of Breast Surgeons Foundation, Co-Chair of the American College of Surgeons National Ultrasound Faculty Breast Imaging Module, and Board Member of the National Accreditation Program for Breast Centers (NAPBC) and the National Consortium of Breast Centers (NCBC). Dr. Fine received his undergraduate degree in Chemistry at Emory University, Atlanta, GA, in 1979 and his MD at the Medical College of Georgia, Augusta, GA, in 1983. He subsequently performed his Surgery Residency at Rush-Presbyterian-St. Luke’s Medical Center from 1983-1988 in association with noted breast care pioneers, Dr. Steven G. Economou and Dr. Kambiz Dowlatshahi. Dr. Fine has received numerous awards including the American Medical Association Physicians Recognition Award, 1991-2010, and most recently recognition as a “Top Doctor” in Memphis Magazine, 2014-2017. A highly sought-after educator and acknowledged thought leader in the use of ultrasound and image-guided technology, Dr. Fine has published numerous articles and written several book chapters related to stereotactic and ultrasound core needle breast biopsy. He continues as a member of several breast research endeavors including the Scientific Advisory Board for the IceCure™ Medical IceSense3 Cryotherapy for Breast Cancer Trial and multiple clinical studies on Image-guided Breast Biopsy Technology. Dr. Fine has served on numerous advisory panels for both established and start-up organizations in developing and bringing to market new technology in the breast space. “I am delighted to be part of the talented team of committed clinicians, scientists, and engineers at TransMed7, all dedicated to provide difference making minimal access medical technology for patients with breast disease,” says Dr. Fine. According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Dr. Fine is a true innovator in the diagnosis and treatment of breast diseases. In addition to being one of the first surgeons in the country to perform stereotactic-guided needle core biopsy, he has since remained on the forefront of education and technology development in the field of image-guided, minimal access breast intervention.” As such, the new appointment looks set to provide many great opportunities for TransMed7. With particular expertise in both oncologic and cardiovascular disease, TransMed7 and its team of clinicians, scientists, and engineers have developed a portfolio of next- generation platform devices that are expected to be market leaders in their targeted fields of medicine. TransMed7 accomplishes this through application of a wholly new approach in its business plan and structure, enabling these new transformational technologies from rapid development through commercial manufacturing or where appropriate, handoff to our Strategic Partners.